title: Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial.
abstract: BACKGROUND
  Dyshidrotic palmoplantar eczema is a frequent disease often running a chronic relapsing course. Topical glucocorticosteroids form the mainstay of therapy, and alternatives are urgently warranted.
  
  
  OBJECTIVE
  This study was performed to compare the efficacy of tacrolimus (FK506) 0.1% ointment and mometasone furoate 0.1% ointment in the treatment of dyshidrotic palmoplantar eczema.
  
  
  METHODS
  Sixteen patients were included in the study after a randomized, observer-blind, intrapersonal comparison protocol. After a 2-week washout period, the active treatment phase amounted to 4 weeks with twice-daily topical application of test substances and additional use of emollients at will. Thereafter, patients were monitored at weekly intervals up to 8 weeks.
  
  
  RESULTS
  The dyshidrotic area and severity index showed a more than 50% reduction of baseline values after 2 weeks of active treatment both for FK506 (P =.003) and mometasone furoate (P =.022) in palmar areas. After active treatment, a nonsignificant increase in the dyshidrotic area and severity index was seen with FK506 treated areas. Fourteen of 16 patients had recurring symptoms requiring further therapy within 3 weeks after the active treatment phase.
  
  
  CONCLUSIONS
  Treatment with FK506 offers the possibility for rotational therapy with mometasone furoate in long-standing cases of chronic dyshidrotic palmar eczema.
authors.affiliation: Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany. nina.schnopp@lrz.tu-muenchen.de
authors.forename: Christina
authors.initials: C
authors.lastname: Schnopp
authors.forename: Roland
authors.initials: R
authors.lastname: Remling
authors.forename: Matthias
authors.initials: M
authors.lastname: Möhrenschlager
authors.forename: Lorenz
authors.initials: L
authors.lastname: Weigl
authors.forename: Johannes
authors.initials: J
authors.lastname: Ring
authors.forename: Dietrich
authors.initials: D
authors.lastname: Abeck
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011146:Eczema, Dyshidrotic / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy / Q000473:pathology; D005938:Glucocorticoids; D006229:Hand Dermatoses / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D016559:Tacrolimus